

## Roche launches Navify cancer guidelines app

Oct. 24, 2019—[Roche](#) has released the Navify Guidelines app as part of its Navify Decision Support portfolio.

The app embeds in the Navify Tumor Board the latest National Comprehensive Cancer Network clinical practice guidelines in oncology covering the four most common cancers—breast, prostate, non-small cell lung, and colorectal.

When opening a patient case, the app identifies the appropriate guidelines based on the patient's cancer type. Clinicians can then select the intended pathway, click through the digitized decision tree or flowchart, and personalize treatment steps. All Navify Tumor Board participants can access the app, and resulting treatment plans can be exported to be incorporated into a practice's EMR system, sent to patients, and submitted to payers for reimbursement approval.

"The Navify Guidelines app provides clinicians with peace of mind that the latest clinical guidance has been considered in treatment decision-making and monitoring," said Thomas Schinecker, CEO of Roche Diagnostics, in a press release. "The ability to facilitate and track guidelines adherence, personalization, and documentation supports evidence-based care for patients around the globe."

The app is available in the U.S., Canada, Singapore, Australia, New Zealand, Korea, Japan, Taiwan, and Hong Kong.